Deals In Depth: June/July 2013
Executive Summary
In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.
You may also be interested in...
NICE Decision On Arthritis Opens Door For Biosimilars In England
A decision by health technology assessment body NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.
Granules Records Double-Digit Growth On The Back Of New Launches
India’s Granules has grown through increased market penetration of its existing products as well as new product launches. The company is planning to invest in expanding its API capacity, finished dosages and a new multiple unit pellet facility.
EU Business Round-Up: Probi Signs Oriflame Deal, Holland & Barrett Heads To China, Enzymatica Launches On Amazon
The latest European health & wellness business news: Probi partners with Swedish beauty firm Oriflame for probiotic launch; retailer Holland & Barrett enters the Chinese market with Alibaba's Tmall; and Enzymatica sees ColdZyme growth potential on Amazon.